Replies to post #228259 on Biotech Values

[miljenko]

NKTR..AC vote...as expected (after briefing doc and introduction), subsidiary is dead.

Bempeg,...it is definitely approvable drug with value, 3-4 indication: melanoma, RCC, H&NC, and UC.

While they can complete PROPEL (it is NKTR trial before collaboration started, but why were so SLOW after BMY deal???), it does boil down to *what after*?

If Pembro demonstrate better efficacy than Nivo, and it is real possibility, what is BMY incentive to run P3? Purposely delay NSCLC indication development, slow down 214 until something else they pull out of hat??? It is situation that I do not like very much. IF SNY is smart, they should push 707(THOR) + Cemiplimab (REGN) (probably add 2-3 cycle of chemo upfront) and compete for NSCLC!

[DewDiligence]

NKTR—A SeelingAlpha blogger lifted language from my recent tweet:

https://twitter.com/DewDiligence/status/1217249665407750145 (from 1/14/20):

$NKTR JPM Q&A session (20min) was unusually informative. It revealed how colossally chaotic the bempeg program has become and how much time and expense has been squandered. I still think bempeg is likely an approvable drug, however.

https://seekingalpha.com/article/4317787-still-chaos-nektar-value-in-pipeline (from 1/19/20):

...listening to the question and answer session at JPMorgan, I get a sense of a lot of chaos and wasted time and money in the bempeg partnership.

Emphasis added by me.